{"id":"W1998827682","doi":"10.1186/1471-2407-11-420","title":"The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity","year":2011,"lang":"en","type":"article","venue":"BMC Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; Centre for Drug Research and Development; BC Cancer Agency","funders":"National Cancer Institute; Canadian Institutes of Health Research; Canadian Breast Cancer Research Alliance","keywords":"Gefitinib; Trastuzumab; In vivo; Cytostasis; Medicine; Cancer research; Everolimus; Breast cancer; SKBR3; PI3K/AKT/mTOR pathway; Pharmacology; Cell growth; Growth inhibition; Surgical oncology; Vinorelbine; Cancer; Oncology; Signal transduction; Internal medicine; Cytotoxicity; Epidermal growth factor receptor; In vitro; Biology; Chemotherapy; Cisplatin","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005104268,0.0001341803,0.0003857016,0.0000871805,0.00006635727,0.00000802786,0.00005458891,0.00006684159,0.00008525806],"category_scores_gemma":[0.00008401401,0.00010118,0.00005044921,0.0002149368,0.0006034311,0.00009107548,0.00007713902,0.0001799694,2.579656e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001661505,"about_ca_system_score_gemma":0.0004842189,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01285856,"about_ca_topic_score_gemma":0.001907336,"domain_scores_codex":[0.9986297,0.0001544081,0.0003268198,0.0002444001,0.00041901,0.000225585],"domain_scores_gemma":[0.9986964,0.0002947439,0.0002641046,0.0001922303,0.0004587336,0.00009380645],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.003429887,0.0004945843,0.4500293,0.002662983,0.000229116,0.00001409129,0.009053877,0.0000100492,0.500852,0.001166357,0.0007448959,0.0313128],"study_design_scores_gemma":[0.001456053,0.0001596114,0.5823624,0.000915043,0.00005076953,0.00002453002,0.0005229336,0.0002283242,0.4139929,0.0001915097,0.00001752753,0.00007846149],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.996241,0.001481639,0.0000456359,0.0001420421,0.00008030976,0.0004724433,0.0002548232,0.000009095497,0.001272952],"genre_scores_gemma":[0.9988245,0.0007976954,0.0001438905,0.00002164135,0.00006061906,0.00003685868,0.0000013669,0.00002261784,0.0000907999],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.132333,"threshold_uncertainty_score":0.9937149,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04481471223116713,"score_gpt":0.3216014584420963,"score_spread":0.2767867462109291,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}